首页 > 最新文献

Expert Review of Clinical Pharmacology最新文献

英文 中文
Reducing the risk of death - a possible outcome in COPD patients. 降低死亡风险--慢性阻塞性肺病患者的一种可能结果。
IF 3.6 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-09-26 DOI: 10.1080/17512433.2024.2408272
Mauro Maniscalco, Luigino Calzetta, Paola Rogliani, Mario Cazzola

Introduction: COPD is a leading cause of global mortality, particularly under-recognized and under-diagnosed. In 2020, it was the sixth leading cause of death in the US and has contributed to 4.72% of all-cause mortality (ACM) according to the Global Burden of Disease Study 2017. Factors influencing COPD-related mortality include smoking, aging populations, comorbidities, sarcopenia, physical capacity, and lack of effective treatments.

Areas covered: This review discusses various factors influencing COPD-related mortality and analyzes observational studies and pivotal RCTs evaluating the impact of different therapies on ACM.

Expert opinion: COPD significantly impacts ACM, necessitating effective management strategies. Smoking cessation is crucial in reducing mortality risk. Exacerbation management and comorbidity treatment are essential to improve patient outcomes. Various therapeutic interventions, such as smoking cessation, vaccination, long-term oxygen therapy, and lung volume reduction surgery, have shown benefits in reducing mortality. Pharmacotherapies might reduce the risk of mortality, although the current scientific evidences remain inconclusive. Advances in pharmacological interventions, tailored treatment plans, and physical activity programs are vital. More robust and long-term studies, focusing on real-world data and addressing biases in treatment allocation, are needed to conclusively determine the efficacy of different therapies in reducing ACM in COPD patients.

导言:慢性阻塞性肺病是导致全球死亡的主要原因,尤其是认识不足和诊断不足。根据《2017 年全球疾病负担研究》,2020 年慢性阻塞性肺病是美国第六大死因,占全因死亡率(ACM)的 4.72%。影响慢性阻塞性肺疾病相关死亡率的因素包括吸烟、人口老龄化、合并症、肌肉疏松症、体能以及缺乏有效的治疗方法:本综述讨论了影响慢性阻塞性肺病相关死亡率的各种因素,并分析了评估不同疗法对ACM影响的观察性研究和关键RCT:专家观点:慢性阻塞性肺病对急性心肌梗死有重大影响,因此必须采取有效的管理策略。戒烟对降低死亡风险至关重要。病情加重管理和合并症治疗对改善患者预后至关重要。各种治疗干预措施,如戒烟、疫苗接种、长期氧疗和肺容积缩小手术,都显示出降低死亡率的益处。药物治疗可降低死亡风险,但目前的科学证据仍不确定。药物干预、量身定制的治疗计划和体育锻炼计划的进步至关重要。要想最终确定不同疗法在减少慢性阻塞性肺疾病患者 ACM 方面的疗效,还需要开展更多稳健而长期的研究,重点关注真实世界的数据,并解决治疗分配中的偏差问题。
{"title":"Reducing the risk of death - a possible outcome in COPD patients.","authors":"Mauro Maniscalco, Luigino Calzetta, Paola Rogliani, Mario Cazzola","doi":"10.1080/17512433.2024.2408272","DOIUrl":"10.1080/17512433.2024.2408272","url":null,"abstract":"<p><strong>Introduction: </strong>COPD is a leading cause of global mortality, particularly under-recognized and under-diagnosed. In 2020, it was the sixth leading cause of death in the US and has contributed to 4.72% of all-cause mortality (ACM) according to the Global Burden of Disease Study 2017. Factors influencing COPD-related mortality include smoking, aging populations, comorbidities, sarcopenia, physical capacity, and lack of effective treatments.</p><p><strong>Areas covered: </strong>This review discusses various factors influencing COPD-related mortality and analyzes observational studies and pivotal RCTs evaluating the impact of different therapies on ACM.</p><p><strong>Expert opinion: </strong>COPD significantly impacts ACM, necessitating effective management strategies. Smoking cessation is crucial in reducing mortality risk. Exacerbation management and comorbidity treatment are essential to improve patient outcomes. Various therapeutic interventions, such as smoking cessation, vaccination, long-term oxygen therapy, and lung volume reduction surgery, have shown benefits in reducing mortality. Pharmacotherapies might reduce the risk of mortality, although the current scientific evidences remain inconclusive. Advances in pharmacological interventions, tailored treatment plans, and physical activity programs are vital. More robust and long-term studies, focusing on real-world data and addressing biases in treatment allocation, are needed to conclusively determine the efficacy of different therapies in reducing ACM in COPD patients.</p>","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"1-9"},"PeriodicalIF":3.6,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142307460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Is therapeutic drug monitoring a dancing partner for TNF-α inhibitors in real-world practice? Answers from an updated systematic review and meta-analysis. 治疗药物监测是 TNF-α 抑制剂在实际应用中的舞伴吗?最新系统综述和荟萃分析给出的答案。
IF 3.6 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-09-21 DOI: 10.1080/17512433.2024.2403641
Yang Hu, Zaiwei Song, Yuan Gao, Dan Jiang, Yiwen Ran, Yi Ma, Huibo Li, Rongsheng Zhao

Introduction: This systematic review aimed to determine the effect of therapeutic drug monitoring (TDM) for tumor necrosis factor-α inhibitors (TNF-αI) in immune-mediated inflammatory diseases (IMIDs) based on real-world evidence, as results from published meta-analyses based on randomized controlled trials (RCTs) may not fully capture the nuances of clinical practice due to strict criteria.

Methods: We searched PubMed, Embase, and the Cochrane Library up to 1 August 2023. Cohort studies comparing TDM (proactive and reactive) with empirical management were included. Primary outcome was effectiveness [for IBDs: clinical remission; for rheumatic diseases: clinical remission or low disease activity], with certainty of evidence appraised using the GRADE approach. Secondary outcomes included treatment failure, serious adverse events (SAEs), IMIDs-related surgeries or hospitalizations, and anti-drug antibodies (ADAs) development risk.

Results: Twenty-four cohort studies were included and almost all were on infliximab. For IBDs, compared with empirical management, proactive TDM significantly improved clinical remission (RR = 1.15, 95% CI = 1.04-1.28), reduced IBDs-related surgeries (RR = 0.46, 95% CI = 0.26-0.81), hospitalizations (RR = 0.60, 95% CI = 0.43-0.83), SAEs (RR = 0.23, 95% CI = 0.07-0.76), and ADAs development risk (RR = 0.34, 95% CI = 0.19-0.60). Reactive TDM significantly lowered hospitalization rates and might be cost-effective. Proactive TDM outperformed reactive TDM in secondary outcomes. For rheumatic diseases, benefits of TDM were inconclusive due to limited evidence.

Conclusions: Real-world evidence supports proactive TDM of TNF-αI (particularly infliximab) in IBDs to improve effectiveness, safety, and immunogenicity. However, benefits of TDM for different TNF-αI in other IMIDs remain uncertain.

Protocol registration: www.crd.york.ac.uk/ PROSPERO identifier is CRD42022370846.

导言:由于基于随机对照试验(RCT)的已发表荟萃分析的结果可能因严格的标准而无法完全反映临床实践的细微差别,因此本系统综述旨在根据现实世界的证据确定肿瘤坏死因子-α抑制剂(TNF-αI)治疗药物监测(TDM)在免疫介导的炎症性疾病(IMIDs)中的效果:我们检索了截至 2023 年 8 月 1 日的 PubMed、Embase 和 Cochrane 图书馆。方法:我们检索了截至 2023 年 8 月 1 日的 PubM、Embase 和 Cochrane 图书馆,纳入了比较 TDM(主动和被动)与经验性管理的队列研究。主要结果为有效性[对于IBD:临床缓解;对于风湿性疾病:临床缓解或低疾病活动性],采用GRADE方法评估证据的确定性。次要结果包括治疗失败、严重不良事件(SAEs)、IMIDs相关手术或住院以及抗药抗体(ADAs)发展风险:结果:共纳入了 24 项队列研究,几乎所有研究都涉及英夫利西单抗。对于 IBDs,与经验性治疗相比,主动性 TDM 可显著改善临床缓解(RR = 1.15,95% CI = 1.04-1.28),减少 IBDs 相关手术(RR = 0.46,95% CI = 0.26-0.81)、住院(RR = 0.60,95% CI = 0.43-0.83)、SAEs(RR = 0.23,95% CI = 0.07-0.76)和 ADAs 发展风险(RR = 0.34,95% CI = 0.19-0.60)。反应性 TDM 能明显降低住院率,可能具有成本效益。在次要结果方面,主动式TDM优于被动式TDM。对于风湿性疾病,由于证据有限,TDM的益处尚无定论:真实世界的证据支持对IBD患者的TNF-αI(尤其是英夫利西单抗)进行主动TDM,以提高有效性、安全性和免疫原性。然而,TDM对其他IMIDs中不同TNF-αI的益处仍不确定。协议注册:www.crd.york.ac.uk/ PROSPERO标识符为CRD42022370846。
{"title":"Is therapeutic drug monitoring a dancing partner for TNF-α inhibitors in real-world practice? Answers from an updated systematic review and meta-analysis.","authors":"Yang Hu, Zaiwei Song, Yuan Gao, Dan Jiang, Yiwen Ran, Yi Ma, Huibo Li, Rongsheng Zhao","doi":"10.1080/17512433.2024.2403641","DOIUrl":"10.1080/17512433.2024.2403641","url":null,"abstract":"<p><strong>Introduction: </strong>This systematic review aimed to determine the effect of therapeutic drug monitoring (TDM) for tumor necrosis factor-α inhibitors (TNF-αI) in immune-mediated inflammatory diseases (IMIDs) based on real-world evidence, as results from published meta-analyses based on randomized controlled trials (RCTs) may not fully capture the nuances of clinical practice due to strict criteria.</p><p><strong>Methods: </strong>We searched PubMed, Embase, and the Cochrane Library up to 1 August 2023. Cohort studies comparing TDM (proactive and reactive) with empirical management were included. Primary outcome was effectiveness [for IBDs: clinical remission; for rheumatic diseases: clinical remission or low disease activity], with certainty of evidence appraised using the GRADE approach. Secondary outcomes included treatment failure, serious adverse events (SAEs), IMIDs-related surgeries or hospitalizations, and anti-drug antibodies (ADAs) development risk.</p><p><strong>Results: </strong>Twenty-four cohort studies were included and almost all were on infliximab. For IBDs, compared with empirical management, proactive TDM significantly improved clinical remission (RR = 1.15, 95% CI = 1.04-1.28), reduced IBDs-related surgeries (RR = 0.46, 95% CI = 0.26-0.81), hospitalizations (RR = 0.60, 95% CI = 0.43-0.83), SAEs (RR = 0.23, 95% CI = 0.07-0.76), and ADAs development risk (RR = 0.34, 95% CI = 0.19-0.60). Reactive TDM significantly lowered hospitalization rates and might be cost-effective. Proactive TDM outperformed reactive TDM in secondary outcomes. For rheumatic diseases, benefits of TDM were inconclusive due to limited evidence.</p><p><strong>Conclusions: </strong>Real-world evidence supports proactive TDM of TNF-αI (particularly infliximab) in IBDs to improve effectiveness, safety, and immunogenicity. However, benefits of TDM for different TNF-αI in other IMIDs remain uncertain.</p><p><strong>Protocol registration: </strong>www.crd.york.ac.uk/ PROSPERO identifier is CRD42022370846.</p>","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"1-14"},"PeriodicalIF":3.6,"publicationDate":"2024-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142282636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of fasudil on clinical outcomes of pulmonary hypertension: a systematic review and meta-analysis. 法舒地尔对肺动脉高压临床疗效的影响:系统综述和荟萃分析。
IF 4.4 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-09-13 DOI: 10.1080/17512433.2024.2404688
Wanying Bao,Mengxin Cheng,Xiaoye Chen,Tao Wang,Dan Xu,Hualin Liao,Lei Chen,Fuqiang Wen,Junyun He,Jun Chen
BACKGROUNDPulmonary hypertension (PH) is a life-threatening condition with high mortality, categorized into 5 Groups based on distinct etiologies. Fasudil, a potent vasodilator targeting the RhoA/Rho kinase pathway, holds promise for diverse PH pathologies. However, a comprehensive systematic evaluation of its clinical benefits remains elusive.METHODSWe conducted a systematic search across several databases. Meta-analysis using odds ratio and mean difference was performed, with an assessment of studies' quality and pooled evidence.RESULTSStudies on Group-2 and -3 PH reports eligible data for meta-analysis. Inclusion of 3269 patients with Group-3 PH demonstrated that fasudil significantly increased effective events, FEV1, 6-minute walking distance (6MWD) and arterial PaO2, and decreased mean pulmonary artery pressure (mPAP) and pulmonary artery systolic pressure (PASP); Inclusion of 197 patients with Group-2 PH suggested that fasudil significantly increased 6MWD and PaO2, and decreased PASP. Subgroup analysis revealed no significant difference between dosages of 30 and 60 mg/day, while durations and methods of fasudil administration might affect therapeutic effectiveness in patients with Group-3 PH.CONCLUSIONSBy providing comprehensive and robust evidence, our study favor the beneficial effects of fasudil by enhancing FEV1, 6MWD and PaO2, and reducing mPAP and PASP on patients with Group-3 PH, suggesting fasudil as a viable treatment recommendation for these patients and highlighting the need for further studies to inform healthcare policies.PROTOCOL REGISTRATIONwww.crd.york.ac.uk/prospero identifier is CRD42022308947.
背景肺动脉高压(PH)是一种威胁生命的疾病,死亡率很高,根据不同的病因可分为 5 类。法舒地尔是一种靶向 RhoA/Rho 激酶通路的强效血管扩张剂,有望治疗各种 PH 病症。方法我们在多个数据库中进行了系统性检索。结果关于第 2 组和第 3 组 PH 的研究报告符合荟萃分析的数据要求。纳入3269例3组PH患者的研究表明,法舒地尔能显著增加有效事件、FEV1、6分钟步行距离(6MWD)和动脉PaO2,降低平均肺动脉压(mPAP)和肺动脉收缩压(PASP);纳入197例2组PH患者的研究表明,法舒地尔能显著增加6MWD和PaO2,降低PASP。亚组分析显示,30 毫克/天和 60 毫克/天的剂量之间没有明显差异,而法舒地尔的用药时间和方法可能会影响第 3 组 PH 患者的疗效。结论通过提供全面而有力的证据,我们的研究支持法舒地尔通过提高FEV1、6MWD和PaO2,降低mPAP和PASP对3组PH患者的有益作用,建议将法舒地尔作为这些患者的可行治疗建议,并强调了进一步研究的必要性,以便为医疗保健政策提供信息。PROTOCOL REGISTRATIONwww.crd.york.ac.uk/prospero identifier is CRD42022308947.
{"title":"Effect of fasudil on clinical outcomes of pulmonary hypertension: a systematic review and meta-analysis.","authors":"Wanying Bao,Mengxin Cheng,Xiaoye Chen,Tao Wang,Dan Xu,Hualin Liao,Lei Chen,Fuqiang Wen,Junyun He,Jun Chen","doi":"10.1080/17512433.2024.2404688","DOIUrl":"https://doi.org/10.1080/17512433.2024.2404688","url":null,"abstract":"BACKGROUNDPulmonary hypertension (PH) is a life-threatening condition with high mortality, categorized into 5 Groups based on distinct etiologies. Fasudil, a potent vasodilator targeting the RhoA/Rho kinase pathway, holds promise for diverse PH pathologies. However, a comprehensive systematic evaluation of its clinical benefits remains elusive.METHODSWe conducted a systematic search across several databases. Meta-analysis using odds ratio and mean difference was performed, with an assessment of studies' quality and pooled evidence.RESULTSStudies on Group-2 and -3 PH reports eligible data for meta-analysis. Inclusion of 3269 patients with Group-3 PH demonstrated that fasudil significantly increased effective events, FEV1, 6-minute walking distance (6MWD) and arterial PaO2, and decreased mean pulmonary artery pressure (mPAP) and pulmonary artery systolic pressure (PASP); Inclusion of 197 patients with Group-2 PH suggested that fasudil significantly increased 6MWD and PaO2, and decreased PASP. Subgroup analysis revealed no significant difference between dosages of 30 and 60 mg/day, while durations and methods of fasudil administration might affect therapeutic effectiveness in patients with Group-3 PH.CONCLUSIONSBy providing comprehensive and robust evidence, our study favor the beneficial effects of fasudil by enhancing FEV1, 6MWD and PaO2, and reducing mPAP and PASP on patients with Group-3 PH, suggesting fasudil as a viable treatment recommendation for these patients and highlighting the need for further studies to inform healthcare policies.PROTOCOL REGISTRATIONwww.crd.york.ac.uk/prospero identifier is CRD42022308947.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":"5 1","pages":""},"PeriodicalIF":4.4,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142250019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Analyzing the clinical efficacy and safety of levocetirizine based on its receptor occupancy, intraclass comparison and role in the treatment of CSU: an AROG consensus statement. 根据左西替利嗪的受体占据率、类内比较和在 CSU 治疗中的作用分析其临床疗效和安全性:AROG 共识声明。
IF 3.6 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-09-12 DOI: 10.1080/17512433.2024.2401093
Kabir Sardana, C R Srinivasan, Mukesh Girdhar, Neirita Hazarika, Krina Patel, Narayan Rao, Akshay Jain, Jaspriya Sandhu, Shivani Bansal, Sunil Ghate, Rizwan Haq, Dhruv Premy Agarwal

Introduction: Chronic spontaneous urticaria (CSU) is characterized by urticaria persisting for more than 6 weeks. Antihistamines, notably sgAH (second generation antihistamines) are the first line of treatment for CSU.

Areas covered: This consensus aimed to review the existing research on receptor occupancy of antihistamines, including levocetirizine, and translate its implications in the treatment of CSU. The consensus deliberations were under the banner of the Antihistamine Receptor Occupancy Group (AROG) from India, an expert panel of 12 dermatologists with a mix of institutional and practitioner backgrounds. This group analyzed the existing translational research on the receptor occupancy of levocetirizine to establish the clinical efficacy and safety of levocetirizine in the treatment of CSU using the grading of recommendations assessment, development, and evaluation (GRADE) method vis-a-vis the varied SGAH.

Expert opinion: SGAH constitute the first step in the therapeutic ladder for managing CSU. Levocetirizine has high bioavailability, high affinity and occupancy of the H1 receptor, rapid onset of action, limited distribution and minimal hepatic metabolism. It exhibits significant anti-inflammatory effects at clinically relevant concentrations. The marked receptor occupancy translates to enhanced efficacy as compared to similarly dosed SGAH with the lower cost making it an appropriate drug for chronic use. Receptor occupancy should be the basis of intra-class head-to-head trials in CSU.

导言:慢性自发性荨麻疹(CSU)的特征是荨麻疹持续6周以上,并导致严重的发病率。抗组胺药,尤其是第二代抗组胺药(sgAH)是治疗 CSU 的一线药物:本共识旨在回顾有关抗组胺药(包括左西替利嗪)受体占用的现有转化研究,并确定其在 CSU 治疗中的作用。该共识由来自印度的抗组胺药受体占位小组(AROG)牵头,该小组由来自不同地区的十二名皮肤科专家组成,他们具有不同的机构和从业背景。该共识分析了现有关于左西替利嗪受体占位的转化研究,采用建议评估、开发和评价分级(GRADE)方法,与不同的SGAH.专家意见相比,确定了左西替利嗪治疗CSU的临床疗效和安全性:第二代抗组胺药是治疗CSU的第一步。左西替利嗪的生物利用度高,对H1受体的亲和力和占据率高,起效迅速,分布有限,肝脏代谢极少。在临床相关浓度下,它具有明显的抗炎作用。与类似剂量的 SGAH 相比,其明显的受体占有率可转化为更好的疗效,而且分子成本较低,适合长期使用。受体占用率应作为 CSU 类内头对头试验的基础。
{"title":"Analyzing the clinical efficacy and safety of levocetirizine based on its receptor occupancy, intraclass comparison and role in the treatment of CSU: an AROG consensus statement.","authors":"Kabir Sardana, C R Srinivasan, Mukesh Girdhar, Neirita Hazarika, Krina Patel, Narayan Rao, Akshay Jain, Jaspriya Sandhu, Shivani Bansal, Sunil Ghate, Rizwan Haq, Dhruv Premy Agarwal","doi":"10.1080/17512433.2024.2401093","DOIUrl":"10.1080/17512433.2024.2401093","url":null,"abstract":"<p><strong>Introduction: </strong>Chronic spontaneous urticaria (CSU) is characterized by urticaria persisting for more than 6 weeks. Antihistamines, notably sgAH (second generation antihistamines) are the first line of treatment for CSU.</p><p><strong>Areas covered: </strong>This consensus aimed to review the existing research on receptor occupancy of antihistamines, including levocetirizine, and translate its implications in the treatment of CSU. The consensus deliberations were under the banner of the Antihistamine Receptor Occupancy Group (AROG) from India, an expert panel of 12 dermatologists with a mix of institutional and practitioner backgrounds. This group analyzed the existing translational research on the receptor occupancy of levocetirizine to establish the clinical efficacy and safety of levocetirizine in the treatment of CSU using the grading of recommendations assessment, development, and evaluation (GRADE) method vis-a-vis the varied SGAH.</p><p><strong>Expert opinion: </strong>SGAH constitute the first step in the therapeutic ladder for managing CSU. Levocetirizine has high bioavailability, high affinity and occupancy of the H1 receptor, rapid onset of action, limited distribution and minimal hepatic metabolism. It exhibits significant anti-inflammatory effects at clinically relevant concentrations. The marked receptor occupancy translates to enhanced efficacy as compared to similarly dosed SGAH with the lower cost making it an appropriate drug for chronic use. Receptor occupancy should be the basis of intra-class head-to-head trials in CSU.</p>","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"1-15"},"PeriodicalIF":3.6,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142125239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oral complement factor D inhibitor danicopan for paroxysmal nocturnal hemoglobinuria. 口服补体因子 D 抑制剂达尼可潘治疗阵发性夜间血红蛋白尿。
IF 4.4 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-09-11 DOI: 10.1080/17512433.2024.2403638
Bo Xu,Jiecan Zhou
INTRODUCTIONParoxysmal nocturnal hemoglobinuria (PNH) is a rare hematological disorder characterized by episodic hemolysis, with additional clinical manifestations including thrombosis and bone marrow failure. The US FDA approved a complement factor D inhibitor, danicopan (Voydeya™), previously known as ACH-4471, for the treatment of extravascular hemolysis in adults with PNH on March 29, 2024. The primary purpose of this review is to examine the clinical efficacy and safety of danicopan.AREAS COVEREDWe systematically searched for articles on PubMed, Web of Science, and three publishers Springer, Elsevier, Wiley up to May 6, 2024.EXPERT OPINIONDanicopan acts on the alternative pathway of the complement cascade, preferentially controlling C3 fragment-mediated extravascular hemolysis. Recommended dosage is 150 mg orally three times a day, which can be increased to 200 mg three times a day when necessary. Vaccination is required before administration to prevent infections by encapsulated bacteria. In a pivotal phase 3 trial ALPHA, danicopan significantly increased hemoglobin levels compared to placebo (P<0.0001), 60% of patients experienced an increase in hemoglobin levels of at least 2 g/dL, compared to none in the placebo group (adjusted difference of 47%; P<0.0001). Common adverse events during danicopan treatment include headache and upper respiratory tract infection.
引言 阵发性夜间血红蛋白尿症(PNH)是一种罕见的血液病,以偶发性溶血为特征,并伴有血栓形成和骨髓衰竭等其他临床表现。美国 FDA 于 2024 年 3 月 29 日批准了一种补体因子 D 抑制剂 Danicopan (Voydeya™)(以前称为 ACH-4471),用于治疗成人 PNH 患者的血管外溶血。本综述的主要目的是研究达尼可潘的临床疗效和安全性。涵盖领域我们系统地检索了PubMed、Web of Science以及Springer、Elsevier、Wiley三家出版社截至2024年5月6日的文章。专家观点达尼可潘作用于补体级联的替代途径,优先控制C3片段介导的血管外溶血。建议剂量为口服 150 毫克,每天三次,必要时可增至 200 毫克,每天三次。用药前需接种疫苗,以防止被包裹的细菌感染。在一项关键性的 3 期试验 ALPHA 中,与安慰剂相比,达尼考潘可显著提高血红蛋白水平(P<0.0001),60% 的患者血红蛋白水平至少提高了 2 g/dL,而安慰剂组患者的血红蛋白水平没有提高(调整后差异为 47%;P<0.0001)。达尼可潘治疗期间常见的不良反应包括头痛和上呼吸道感染。
{"title":"Oral complement factor D inhibitor danicopan for paroxysmal nocturnal hemoglobinuria.","authors":"Bo Xu,Jiecan Zhou","doi":"10.1080/17512433.2024.2403638","DOIUrl":"https://doi.org/10.1080/17512433.2024.2403638","url":null,"abstract":"INTRODUCTIONParoxysmal nocturnal hemoglobinuria (PNH) is a rare hematological disorder characterized by episodic hemolysis, with additional clinical manifestations including thrombosis and bone marrow failure. The US FDA approved a complement factor D inhibitor, danicopan (Voydeya™), previously known as ACH-4471, for the treatment of extravascular hemolysis in adults with PNH on March 29, 2024. The primary purpose of this review is to examine the clinical efficacy and safety of danicopan.AREAS COVEREDWe systematically searched for articles on PubMed, Web of Science, and three publishers Springer, Elsevier, Wiley up to May 6, 2024.EXPERT OPINIONDanicopan acts on the alternative pathway of the complement cascade, preferentially controlling C3 fragment-mediated extravascular hemolysis. Recommended dosage is 150 mg orally three times a day, which can be increased to 200 mg three times a day when necessary. Vaccination is required before administration to prevent infections by encapsulated bacteria. In a pivotal phase 3 trial ALPHA, danicopan significantly increased hemoglobin levels compared to placebo (P<0.0001), 60% of patients experienced an increase in hemoglobin levels of at least 2 g/dL, compared to none in the placebo group (adjusted difference of 47%; P<0.0001). Common adverse events during danicopan treatment include headache and upper respiratory tract infection.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":"7 1","pages":""},"PeriodicalIF":4.4,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142222504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association between sodium-glucose cotransporter 2 inhibitors and eye disorders: a systematic review and meta-analysis. 钠-葡萄糖共转运体 2 抑制剂与眼疾之间的关系:系统回顾和荟萃分析。
IF 3.6 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-09-11 DOI: 10.1080/17512433.2024.2399073
Bo Xu, Bo Kang, Fan Tang, Jiecan Zhou, Zunbo He

Introduction: Lowering blood glucose is important to prevent long-term microvascular complications in adults with type 2 diabetes mellitus (T2DM). Various evidence suggests that sodium-glucose cotransporter 2 (SGLT2) inhibitors are beneficial for microvascular diseases. This study was designed to investigate whether SGLT2 inhibitors have an effect on eye disorders.

Methods: We searched PubMed, Web of Science, and ClinicalTrials.gov for randomized, double-blind, placebo-controlled trials with at least 24 weeks of follow-up up to 20 December 2023. Mantel-Haenszel statistical method, risk ratios (RRs) and 95% confidence intervals (CIs) were used to analyze the binary variables.

Results: We included a total of 40 studies covering 104,586 participants. T2DM was present in 84.5% of the subjects. SGLT2 inhibitors had no significant effect on overall eye events compared to placebo (RR 0.99; 95%CI 0.86-1.15; p = 0.91), nor did subgroup analysis. We did not observe significant heterogeneity (I2 = 0; p = 0.99). Analysis of all secondary outcomes showed that SGLT2 inhibitors did not cause a significantly different effect from placebo. Meta-analysis in the entire T2DM population showed results consistent with those in the overall population.

Conclusion: SGLT2 inhibitors did not have a significant effect on eye disorders during treatment, regardless of baseline conditions and duration of treatment.

简介降低血糖对于预防成人 2 型糖尿病(T2DM)患者的长期微血管并发症非常重要。各种证据表明,钠-葡萄糖共转运体 2(SGLT2)抑制剂对微血管疾病有益。本研究旨在探讨 SGLT2 抑制剂是否对眼部疾病有影响:我们在PubMed、Web of Science和ClinicalTrials.gov上检索了截至2023年12月20日至少随访24周的随机、双盲、安慰剂对照试验。采用曼特尔-海恩泽尔统计方法、风险比(RR)和95%置信区间(CI)分析二元变量:我们共纳入了 40 项研究,覆盖 104 586 名参与者。84.5%的受试者患有 T2DM。与安慰剂相比,SGLT2 抑制剂对总体眼部事件没有显著影响(RR 0.99;95%CI 0.86-1.15;P = 0.91),亚组分析也是如此。我们没有观察到明显的异质性(I2 = 0;P = 0.99)。对所有次要结果的分析表明,SGLT2 抑制剂与安慰剂的效果没有明显差异。对所有 T2DM 患者进行的 Meta 分析表明,结果与整个人群的结果一致:结论:无论基线条件和疗程长短如何,SGLT2 抑制剂在治疗期间都不会对眼部疾病产生显著影响。
{"title":"Association between sodium-glucose cotransporter 2 inhibitors and eye disorders: a systematic review and meta-analysis.","authors":"Bo Xu, Bo Kang, Fan Tang, Jiecan Zhou, Zunbo He","doi":"10.1080/17512433.2024.2399073","DOIUrl":"10.1080/17512433.2024.2399073","url":null,"abstract":"<p><strong>Introduction: </strong>Lowering blood glucose is important to prevent long-term microvascular complications in adults with type 2 diabetes mellitus (T2DM). Various evidence suggests that sodium-glucose cotransporter 2 (SGLT2) inhibitors are beneficial for microvascular diseases. This study was designed to investigate whether SGLT2 inhibitors have an effect on eye disorders.</p><p><strong>Methods: </strong>We searched PubMed, Web of Science, and ClinicalTrials.gov for randomized, double-blind, placebo-controlled trials with at least 24 weeks of follow-up up to 20 December 2023. Mantel-Haenszel statistical method, risk ratios (RRs) and 95% confidence intervals (CIs) were used to analyze the binary variables.</p><p><strong>Results: </strong>We included a total of 40 studies covering 104,586 participants. T2DM was present in 84.5% of the subjects. SGLT2 inhibitors had no significant effect on overall eye events compared to placebo (RR 0.99; 95%CI 0.86-1.15; <i>p</i> = 0.91), nor did subgroup analysis. We did not observe significant heterogeneity (I<sup>2</sup> = 0; <i>p</i> = 0.99). Analysis of all secondary outcomes showed that SGLT2 inhibitors did not cause a significantly different effect from placebo. Meta-analysis in the entire T2DM population showed results consistent with those in the overall population.</p><p><strong>Conclusion: </strong>SGLT2 inhibitors did not have a significant effect on eye disorders during treatment, regardless of baseline conditions and duration of treatment.</p>","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"1-9"},"PeriodicalIF":3.6,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142105883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction. 更正。
IF 3.6 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-09-08 DOI: 10.1080/17512433.2024.2402165
{"title":"Correction.","authors":"","doi":"10.1080/17512433.2024.2402165","DOIUrl":"https://doi.org/10.1080/17512433.2024.2402165","url":null,"abstract":"","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"1"},"PeriodicalIF":3.6,"publicationDate":"2024-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142153523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Drug related adverse event assessment in neonates in clinical trials and clinical care. 在临床试验和临床护理中对新生儿进行药物相关不良事件评估。
IF 3.6 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-09-01 Epub Date: 2024-08-13 DOI: 10.1080/17512433.2024.2390927
Nadir Yalcin, John van den Anker, Samira Samiee-Zafarghandy, Karel Allegaert

Introduction: Assessment of drug-related adverse events is essential to fully understand the benefit-risk balance of any drug exposure, weighing efficacy versus safety. This is needed for both drug labeling and clinical decision-making. Assessment is based on seriousness, severity and causality, be it more difficult to apply in neonates. Adverse event detection or prevention in the neonatal clinical setting is also more complicated because of polypharmacy, and off-label or unlicensed pharmacotherapy.

Areas covered: Tools became available to assess severity and causality of adverse events in neonates recruited in clinical trials. The first version of the Neonatal Adverse Event severity score (NAESS) reduced the inter-observer variability. Causality tools like the Naranjo score were also tailored to neonates. These tools are also instrumental to support proactive pharmacovigilance in clinical care, while multidisciplinary care teams and computerized pharmacovigilance using advanced data analysis, like machine learning are emerging approaches to develop effective decision strategies.

Expert opinion: All stakeholders involved in development of medicines or its clinical use should be aware of the limitations of the currently available assessment tools. Extension and optimization of these tools, advanced data analysis approaches, and capturing the variability in time-dependent physiology are warranted to improve pharmacovigilance in neonates.

导言:评估与药物相关的不良事件对于充分了解任何药物暴露的效益与风险平衡、权衡疗效与安全性至关重要。这对于药物标签和临床决策都是必需的。评估以严重性、严重程度和因果关系为基础,但在新生儿中较难应用。新生儿临床环境中的不良事件检测或预防工作也更加复杂,因为新生儿使用多种药物、标签外或无证药物治疗:目前已有工具可用于评估临床试验中新生儿不良事件的严重性和因果关系。第一版新生儿不良事件严重程度评分(NAESS)减少了观察者之间的差异。纳兰霍评分等因果关系工具也是为新生儿量身定制的。这些工具还有助于支持临床护理中的前瞻性药物警戒,而多学科护理团队和使用先进数据分析(如机器学习)的计算机化药物警戒则是制定有效决策策略的新兴方法:专家意见:所有参与药品研发或临床使用的相关人员都应认识到现有评估工具的局限性。为了改善新生儿的药物警戒,有必要对这些工具进行扩展和优化,采用先进的数据分析方法,并捕捉随时间变化的生理变化。
{"title":"Drug related adverse event assessment in neonates in clinical trials and clinical care.","authors":"Nadir Yalcin, John van den Anker, Samira Samiee-Zafarghandy, Karel Allegaert","doi":"10.1080/17512433.2024.2390927","DOIUrl":"10.1080/17512433.2024.2390927","url":null,"abstract":"<p><strong>Introduction: </strong>Assessment of drug-related adverse events is essential to fully understand the benefit-risk balance of any drug exposure, weighing efficacy versus safety. This is needed for both drug labeling and clinical decision-making. Assessment is based on seriousness, severity and causality, be it more difficult to apply in neonates. Adverse event detection or prevention in the neonatal clinical setting is also more complicated because of polypharmacy, and off-label or unlicensed pharmacotherapy.</p><p><strong>Areas covered: </strong>Tools became available to assess severity and causality of adverse events in neonates recruited in clinical trials. The first version of the Neonatal Adverse Event severity score (NAESS) reduced the inter-observer variability. Causality tools like the Naranjo score were also tailored to neonates. These tools are also instrumental to support proactive pharmacovigilance in clinical care, while multidisciplinary care teams and computerized pharmacovigilance using advanced data analysis, like machine learning are emerging approaches to develop effective decision strategies.</p><p><strong>Expert opinion: </strong>All stakeholders involved in development of medicines or its clinical use should be aware of the limitations of the currently available assessment tools. Extension and optimization of these tools, advanced data analysis approaches, and capturing the variability in time-dependent physiology are warranted to improve pharmacovigilance in neonates.</p>","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"803-816"},"PeriodicalIF":3.6,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141916492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The evolution of clinical trials for pediatric pulmonary hypertension: are the needs of patients and their caregivers being met? 小儿肺动脉高压临床试验的演变:是否满足了患者及其护理人员的需求?
IF 3.6 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-09-01 DOI: 10.1080/17512433.2024.2396119
Julie Wacker, Raphael Joye, Leon Genecand, Frederic Lador, Maurice Beghetti

Introduction: Pediatric pulmonary hypertension is a rare condition. Survival remains poor in the current management era. There is a lack of data regarding the medical management of pediatric pulmonary hypertension and most pulmonary vasodilators are used off-label in children.

Areas covered: Pediatric pulmonary hypertension clinical trials' design and realization face many hurdles, including poor recruitment, limited available pharmacologic and physiologic data in children of various ages, ethical issues, and the lack of validated trial endpoint. Innovative clinical trial designs have emerged and may allow us to overcome some of these issues. Extrapolation of adult data to children, with additional pharmacokinetic and safety data, remains extremely important and valid in etiologies where the pediatric and the adult pathophysiologies are believed to be similar.

Expert opinion: Close collaboration between sponsors, regulators, patients, caregivers, physicians and researchers is necessary to develop efficacious and safe drugs for pediatric pulmonary hypertension. The increasing involvement of patients' and caregivers' participation in the development of clinical trials should help shape future research that is feasible and meaningful to the patients.

简介小儿肺动脉高压是一种罕见病。在目前的治疗时代,存活率仍然很低。有关小儿肺动脉高压医疗管理的数据匮乏,大多数肺血管扩张剂在儿童中的使用都是非标的:小儿肺动脉高压临床试验的设计和实现面临许多障碍,包括招募不足、不同年龄儿童的药物和生理数据有限、伦理问题以及缺乏有效的试验终点。创新的临床试验设计已经出现,或许能让我们克服其中的一些问题。将成人数据外推至儿童,并提供更多的药代动力学和安全性数据,对于认为儿童和成人病理生理学相似的病因仍极为重要和有效:赞助商、监管机构、患者、护理人员、医生和研究人员之间的紧密合作对于开发有效、安全的小儿肺动脉高压药物十分必要。患者和护理人员越来越多地参与到临床试验的开发过程中,这应有助于形成对患者可行且有意义的未来研究。
{"title":"The evolution of clinical trials for pediatric pulmonary hypertension: are the needs of patients and their caregivers being met?","authors":"Julie Wacker, Raphael Joye, Leon Genecand, Frederic Lador, Maurice Beghetti","doi":"10.1080/17512433.2024.2396119","DOIUrl":"10.1080/17512433.2024.2396119","url":null,"abstract":"<p><strong>Introduction: </strong>Pediatric pulmonary hypertension is a rare condition. Survival remains poor in the current management era. There is a lack of data regarding the medical management of pediatric pulmonary hypertension and most pulmonary vasodilators are used off-label in children.</p><p><strong>Areas covered: </strong>Pediatric pulmonary hypertension clinical trials' design and realization face many hurdles, including poor recruitment, limited available pharmacologic and physiologic data in children of various ages, ethical issues, and the lack of validated trial endpoint. Innovative clinical trial designs have emerged and may allow us to overcome some of these issues. Extrapolation of adult data to children, with additional pharmacokinetic and safety data, remains extremely important and valid in etiologies where the pediatric and the adult pathophysiologies are believed to be similar.</p><p><strong>Expert opinion: </strong>Close collaboration between sponsors, regulators, patients, caregivers, physicians and researchers is necessary to develop efficacious and safe drugs for pediatric pulmonary hypertension. The increasing involvement of patients' and caregivers' participation in the development of clinical trials should help shape future research that is feasible and meaningful to the patients.</p>","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"793-801"},"PeriodicalIF":3.6,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142016830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sodium-glucose co-transporter 2 inhibition and acute myocardial infarction: the DAPA-MI and EMPACT-MI trials. 钠-葡萄糖共转运体 2 抑制与急性心肌梗死:DAPA-MI 和 EMPACT-MI 试验。
IF 3.6 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-09-01 Epub Date: 2024-08-12 DOI: 10.1080/17512433.2024.2390921
Muhammad Adnan Zaman, Sidra Kalsoom
{"title":"Sodium-glucose co-transporter 2 inhibition and acute myocardial infarction: the DAPA-MI and EMPACT-MI trials.","authors":"Muhammad Adnan Zaman, Sidra Kalsoom","doi":"10.1080/17512433.2024.2390921","DOIUrl":"10.1080/17512433.2024.2390921","url":null,"abstract":"","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"771-775"},"PeriodicalIF":3.6,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141901441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Expert Review of Clinical Pharmacology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1